JAK inhibitors for the treatment of autoimmune and inflammatory diseases

Y Jamilloux, T El Jammal, L Vuitton… - Autoimmunity …, 2019 - Elsevier
Cytokines play a central role in the pathophysiology of autoimmune and inflammatory
diseases. Several cytokines signal through the JAK-STAT pathway, which is now recognized …

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: a network meta‐analysis

H Wan, H Jia, T Xia, D Zhang - Dermatologic Therapy, 2022 - Wiley Online Library
Janus kinase (JAK) inhibitors have become promising treatments for atopic dermatitis (AD),
however no study directly comparing JAK inhibitors with each other has been reported. We …

Skin pigmentation types, causes and treatment—a review

AM Thawabteh, A Jibreen, D Karaman, A Thawabteh… - Molecules, 2023 - mdpi.com
Human skin pigmentation and melanin synthesis are incredibly variable, and are impacted
by genetics, UV exposure, and some drugs. Patients' physical appearance, psychological …

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two …

E Guttman-Yassky, HD Teixeira, EL Simpson, KA Papp… - The Lancet, 2021 - thelancet.com
Background Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory
potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy …

Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib

S Ferreira, E Guttman-Yassky, T Torres - American journal of clinical …, 2020 - Springer
Atopic dermatitis is a common, chronic, immune-mediated disease associated with several
comorbidities. Elevated levels of T helper (Th) 2, Th22, and also some Th1 and Th17 …

Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs

M Gadina, C Johnson, D Schwartz… - Journal of leukocyte …, 2018 - academic.oup.com
In this era, it is axiomatic that cytokines have critical roles in cellular development and
differentiation, immune homeostasis, and host defense. Equally, dysregulation of cytokines …

Emerging therapies for atopic dermatitis: JAK inhibitors

DG Cotter, D Schairer, L Eichenfield - Journal of the American Academy of …, 2018 - Elsevier
The Janus kinase–signal transducer and activator of transcription pathway is a conserved
master regulator of immunity and myeloproliferation. Advanced understanding of this …

Enhancing intradermal delivery of tofacitinib citrate: Comparison between powder-loaded hollow microneedle arrays and dissolving microneedle arrays

Á Cárcamo-Martínez, B Mallon, QK Anjani… - International Journal of …, 2021 - Elsevier
Autoimmune-mediated inflammatory skin diseases, such as psoriasis, alopecia areata, and
vitiligo, have been reported as the 4th leading cause of nonfatal disease burden worldwide …

Dermatomyositis: an update on diagnosis and treatment

GA Cobos, A Femia, RA Vleugels - American Journal of Clinical …, 2020 - Springer
Dermatomyositis is a rare inflammatory disease with characteristic cutaneous findings and
varying amounts of systemic involvement. Patients may present with skin disease alone …

Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata

AM Montilla, F Gómez-García, PJ Gómez-Arias… - Dermatology and …, 2019 - Springer
Abstract Introduction The JAK/STAT signaling pathway is involved in the immune-mediated
inflammatory skin diseases atopic dermatitis (AD), vitiligo, and alopecia areata (AA), and …